Skip to Content
Morningstar

Oncternal Therapeutics Inc ONCT

Morningstar Rating
Unlock
Stock XNAS Rating as of
$8.83 +0.29 (3.34%)
View Full Chart
As of Delayed Price Open
Unlock our analysis with Morningstar Investor
Start Free Trial

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

View History
ONCT is trading at a 68% discount.
Price
$8.56
Fair Value
$21.19
Uncertainty
Extreme
1-Star Price
$591.87
5-Star Price
$4.33
Economic Moat
Xbvv
Capital Allocation
—
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ONCT is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$8.55
Day Range
$8.83–8.83
52-Week Range
$5.57–13.14
Bid/Ask
$8.52 / $8.99
Market Cap
$26.13 Mil
Volume/Avg
274 / 8,297

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
27
Website
https://www.oncternal.com

Competitors

Valuation

View More
Metric
ONCT
LLY
MRK
Price/Earnings (Normalized)
 —87.2784.62
Price/Book Value
 0.8664.538.55
Price/Sales
 —19.385.38
Price/Cash Flow
 —90.6621.26
Price/Earnings
ONCT
LLY
MRK

Financial Strength

Metric
ONCT
LLY
MRK
Quick Ratio
 6.710.520.68
Current Ratio
 6.940.941.25
Interest Coverage
 —14.132.33
Quick Ratio
ONCT
LLY
MRK

Profitability

Metric
ONCT
LLY
MRK
Return on Assets (Normalized)
 −62.06%10.22%3.59%
Return on Equity (Normalized)
 −70.85%52.03%9.12%
Return on Invested Capital (Normalized)
 −75.41%19.27%5.88%
Return on Assets
ONCT
LLY
MRK
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRTmbyjzpdXnsk$562.4 Bil
VRTX
Vertex Pharmaceuticals IncVlgxxhpwWvwgcr$103.6 Bil
REGN
Regeneron Pharmaceuticals IncPwnyqjbvgKbwnt$99.5 Bil
MRNA
Moderna IncTzzhvdbgNcr$38.8 Bil
ARGX
argenx SE ADRLphbhnzmRppvn$22.3 Bil
BNTX
BioNTech SE ADRLbbqxlxkxHkvr$21.2 Bil
ALNY
Alnylam Pharmaceuticals IncPkmbxlbWzdlfl$18.2 Bil
BMRN
Biomarin Pharmaceutical IncGcgzkgwjLnzhd$17.3 Bil
RPRX
Royalty Pharma PLC Class AXrjymbxjDbgcqy$12.5 Bil
INCY
Incyte CorpDwgdgvbmBsnxpc$11.6 Bil

Sponsor Center